Scynexis Stock Price, News & Analysis

SCYNEXIS announced interim data from its Phase 3 FURI and CARES studies showing positive results for oral ibrexafungerp in treating refractory fungal infections. The studies involve over 130 patients, indicating a 61.1% rate of clinical improvement across both trials. Ibrexafungerp addresses severe infections caused by drug-resistant Candida species, with a notable 88.9% response rate in the CARES study. Results will be shared at the ECCMID in April 2022, reinforcing SCYNEXIS's initiative to build a robust antifungal franchise.

SCYNEXIS, Inc. (NASDAQ: SCYX) has initiated an underwritten public offering of common stock and warrants, including pre-funded warrants. The underwriters may purchase up to an additional 15% of the offered shares within 30 days. This offering is subject to market conditions, and no guarantees are made regarding its completion or terms. Guggenheim Securities is the book-running manager. The offering is based on a shelf registration statement filed with the SEC, originally effective in January 2021. SCYNEXIS is known for its lead antifungal drug, ibrexafungerp, aimed at treating drug-resistant infections.

SCYNEXIS, Inc. (NASDAQ: SCYX) has announced the presentation of interim data from its Phase 3 FURI and CARES studies focusing on ibrexafungerp, a novel antifungal agent, at the 32nd ECCMID in Lisbon, Portugal, from April 23-26, 2022. Highlights include an oral presentation on patient outcomes and various poster sessions on treatment efficacy for serious fungal infections including Candida auris. The company emphasizes its commitment to addressing drug-resistant infections and the potential of ibrexafungerp as a broad-spectrum antifungal therapy.

SCYNEXIS has announced that BREXAFEMME (ibrexafungerp tablets) is now accessible to about 55% of commercially insured U.S. patients, covering more than 93 million lives. This first-in-class oral antifungal treatment addresses an unmet need for vaginal yeast infections, particularly in resistant cases. The drug, approved by the FDA in June 2021, demonstrates efficacy against Candida species. The company anticipates ongoing increases in insurance coverage and prescription volumes as they pursue broader access for women.

SCYNEXIS, Inc. (NASDAQ: SCYX) announced its participation in three women’s health conferences throughout April 2022, showcasing its commitment to advancing women’s health. The company, known for developing BREXAFEMME (ibrexafungerp), the first oral treatment for vaginal yeast infections approved in over 20 years, aims to discuss innovative treatments. The conferences include the ACOOG Annual Conference (April 3-8), NBNPA Conference (April 29-30), and Ms. Medicine Women’s Health Conference (April 28-30). Each event will address significant advancements in women’s health.

SCYNEXIS reported significant achievements for 2021, with BREXAFEMME generating $1.1 million in net revenues. The fourth quarter alone saw revenues of $0.6 million. The product is now covered by commercial insurance representing 48% of insured lives. The successful CANDLE Phase 3 trial claims statistical superiority over placebo for ibrexafungerp in treating recurrent vulvovaginal candidiasis. SCYNEXIS has projected a cash runway extending into the second quarter of 2023.

SCYNEXIS, Inc. (NASDAQ: SCYX) will announce its fourth quarter and full year 2021 financial results on March 29, 2022. The company, dedicated to developing innovative medicines for difficult-to-treat infections, plans to hold a conference call at 8:30 a.m. EDT to discuss the results. SCYNEXIS's lead product, ibrexafungerp, is a systemic antifungal approved by the FDA on June 1, 2021, and is set for launch in the U.S. as BREXAFEMME. The company is continuing investigations into ibrexafungerp for other significant fungal infections.

SCYNEXIS, Inc. (NASDAQ: SCYX) announced grants of stock options and Restricted Stock Units (RSUs) to three new employees, totaling 28,000 stock options at an exercise price of $4.18 and 11,500 RSUs. This move aims to attract talent in the biotechnology sector focusing on innovative treatments for drug-resistant fungal infections. The options will vest over a four-year period, while the RSUs will vest over three years. These grants are part of SCYNEXIS’ 2015 Inducement Award Plan, aligned with their mission to develop medicines like ibrexafungerp, aimed at combating serious fungal infections.